Research Library
The following scientific abstracts have been reviewed by the Dr. Eliaz staff for relevance to the ingredient Artemisinin. Click on any of the following abstract titles to see the details of the abstract.
Title: Dihydroartemisinin is an inhibitor of ovarian cancer cell growth.
Authors: Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ.
Journal: Acta Pharmacol Sin. 2007 Jul;28(7):1045-56.
Title: Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Authors: Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM.
Journal: Eur J Clin Pharmacol. 2005 Nov;61(10):755-61. Epub 2005 Oct 29.
Title: Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Authors: Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G.
Journal: Oncol Rep. 2005 Dec;14(6):1599-603.
Title: Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds.
Authors: Lai H, Sasaki T, Singh NP.
Journal: Expert Opin Ther Targets. 2005 Oct;9(5):995-1007.
Title: Synthesis and Immunosuppressive Activity of New Artemisinin Derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl Aliphatic Acids and Esters.
Authors: Yang ZS, Zhou WL, Sui Y, Wang JX, Wu JM, Zhou Y, Zhang Y, He PL, Han JY, Tang W, Li Y, Zuo JP.
Journal: J Med Chem. 2005 Jul 14;48(14):4608-4617.
Title: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate.
Authors: Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T.
Journal: Biochem Pharmacol. 2004 Dec 15;68(12):2359-66.
Title: Antimalarial dihydroartemisinin also inhibits angiogenesis.
Authors: Chen HH, Zhou HJ, Wang WQ, Wu GD.
Journal: Cancer Chemother Pharmacol. 2004 Jan 22
Title: Turning an 'Achilles' Heel' into an asset - activation of HIF-1alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage.
Authors: McCarty MF.
Journal: Med Hypotheses. 2003 Oct;61(4):509-11.
Title: Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro.
Authors: Chen HH, Zhou HJ, Fang X.
Journal: Pharmacol Res. 2003 Sep;48(3):231-6.
Title: Neuropathologic toxicity of artemisinin derivatives in a mouse model.
Authors: Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S, White NJ.
Journal: Am J Trop Med Hyg. 2002 Oct;67(4):423-9.
Title: Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells.
Authors: Sadava D, Phillips T, Lin C, Kane SE.
Journal: Cancer Lett. 2002 May 28;179(2):151-6.
Title: Antiulcerogenic activity of some sesquiterpene lactones isolated from Artemisia annua.
Authors: Foglio MA, Dias PC, Antonio MA, Possenti A, Rodrigues RA, da Silva EF, Rehder VL, de Carvalho JE.
Journal: Planta Med. 2002 Jun;68(6):515-8
Title: Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.
Authors: Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M.
Journal: Antimicrob Agents Chemother. 2002 Apr;46(4):1026-31
Title: Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance.
Authors: Mukanganyama S, Widersten M, Naik YS, Mannervik B, Hasler JA.
Journal: Int J Cancer. 2002 Feb 10;97(5):700-5.
Title: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells.
Authors: Singh NP, Lai H.
Journal: Life Sci. 2001 Nov 21;70(1):49-56.
Title: In vitro evidence for auto-induction of artemisinin metabolism in the rat.
Authors: Gupta S, Svensson US, Ashton M.
Journal: Eur J Drug Metab Pharmacokinet. 2001 Jul-Sep;26(3):173-8.